Last patient completes the EU Phase III study of Diamyd® antigen based therapy for type 1 diabetes

The final patient has performed the last visit of the main study period in Diamyd Medical’s European Phase III study. Treatment with the antigen based therapy Diamyd® is made to investigate whether beta cell function and thereby blood sugar control can be preserved in children and adolescents with new onset type 1 diabetes. The top line results from this study are expected to be reported as planned, in late spring 2011.The last patient in the EU Diamyd Phase III clinical study has completed the 15-month visit, meaning that all patients in this study have completed the main 15 month study